Clinical efficacy of rh-bFGF on gynecological refractory wounds

Abstract

Objective To investigate the curative effects of external recombinant human basic fibroblast growth factor (rh-bFGF) on gynecological refractory wounds. Methods Fourty-six patients who developed refractory wounds after operation in Department of Gynaecology of the First Affiliated Hospital of Zhengzhou University, from September 2014 to September 2018, were selected as research objects. Among them, 23 patients who were treated with the rh-bFGF were allocated into observation group. Another 23 patients whose wounds were routinely disinfected and cleaned were selected as control group. Wound healing rate and remission time of the two groups were recorded and compared. Results At 1 week and 2 weeks after the review, there was a significant difference in the healing rate of refractory vaginal stump wound between observation group and contro group(18.75%vs. 3.13%, 93.75%vs. 43.75%), P<0.01; and there was a significant difference in remission time of refractory vaginal stump wound between observation group and control group[(39.59±3.03)d vs. (45.34±2.98)d], P<0.01. At 1 week and 2 weeks after the review, the refractory wound healing rate of the vaginoplasty of observation group was statistically significant different from that of control group(14.29% vs. 0.00%, 76.19% vs. 28.57%), P<0.01, and the wound remission time of observation group was statistically significant different from that of control group[(41.19±3.43)d vs. (48.10±3.36)d], P<0.01. Conclusions rh-bFGF is conductive to remission of gynecological refractory wounds, with noticeable effect. No significant organ damage or adverse reactions to heart, liver and kidney is found during the medication. Key words: Recombinant human basic fibroblast growth factor; Refractory wounds; Curative effect